Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.83 |
| ▸ | LIPE | Q05469 | 4/20 | 0.60 |
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.49 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.49 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29494845 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNACYP2C9TSHRAPEX1 | |
| SCHEMBL7172986 | 0.98 | SMN1; SMN2 (0.96) | SMN1; SMN2LMNACYP2C9TSHRAPEX1 | |
| SCHEMBL8686510 | 0.91 | SMN1; SMN2 (0.83) | SMN1; SMN2LMNACYP2C9TSHRAPEX1 | |
| SCHEMBL12386871 | 0.91 | LMNA (0.83) | SMN1; SMN2LMNACYP2C9TSHRAPEX1 | |
| SCHEMBL5647172 | 0.91 | MAPK1 (1.00) | SMN1; SMN2LMNACYP2C9TSHRAPEX1 | |
| SCHEMBL10854830 | 0.89 | MAPK1 (0.97) | SMN1; SMN2LMNACYP2C9TSHRAPEX1 | |
| SCHEMBL5646896 | 0.87 | SMN1; SMN2 (0.75) | SMN1; SMN2LMNACYP2C9TSHRAPEX1 | |
| SCHEMBL10954112 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2LMNACYP2C9TSHRAPEX1 | |
| SCHEMBL5648867 | 0.84 | SMN1; SMN2 (0.72) | SMN1; SMN2LMNACYP2C9TSHRAPEX1 | |
| SCHEMBL11016705 | 0.84 | SMN1; SMN2 (0.72) | SMN1; SMN2LMNACYP2C9TSHRAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698662-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| EP-4541898-A2 | LIVER-SPECIFIC INDUCIBLE PROMOTERS AND METHODS OF USE THEREOF | AskBio Inc. (US) | 2025-04-23 | — | — | EP | claimed |
| EP-3911751-B1 | LIVER-SPECIFIC INDUCIBLE PROMOTERS AND METHODS OF USE THEREOF | ASKBIO INC (US) | 2025-02-26 | — | — | EP | claimed |
| WO-2024220449-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) | 2024-10-24 | — | — | WO | claimed |
| US-20220111078-A1 | LIVER-SPECIFIC INDUCIBLE PROMOTERS AND METHODS OF USE THEREOF | SYNPROMICS LIMITED (GB) | 2022-04-14 | — | — | US | claimed |
| CN-113614234-A | Liver-specific inducible promoters and methods of use thereof | 塞普洛麦克斯有限公司 | 2021-11-05 | — | — | CN | claimed |
| US-20120003335-A1 | CONSTITUTIVE ANDROSTANE RECEPTOR (CAR) AS A THERAPEUTIC TARGET FOR OBESITY AND TYPE TWO DIABETES | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-01-05 | — | — | US | claimed |
| US-7365160-B2 | Mutated constitutively active nuclear orphan receptor | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-04-29 | — | — | US | claimed |
| US-20050107590-A1 | Mutated constitutively active nuclear ophan receptor | GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE | 2005-05-19 | — | — | US | claimed |
| WO-2004034029-A2 | SCREENING SYSTEMS AND METHODS FOR IDENTIFYING MODULATORS OF XENOBIOTIC METABOLISM | BAYLOR COLLEGE OF MEDICINE (US) | 2004-04-22 | — | — | WO | claimed |
| US-20030150004-A1 | Screening systems and methods for identifying modulators of xenobiotic metabolism | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-08-07 | — | — | US | claimed |
| US-4275212-A | CONVERSION OF BIS(PYRIDINYL OXY) BENZENE BY-PRODUCTS WITH EXCESS HYDROQUINONE | THE DOW CHEMICAL COMPANY (US) | 1981-06-23 | — | — | US | claimed |
| US-12599665-B2 | Gene fusions for control of genetically modified cells | A2 BIOTHERAPEUTICS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4698662-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12472269-B2 | Liver-specific inducible promoters and methods of use thereof | AskBio Inc. | 2025-11-18 | — | — | US | disclosed |
| EP-4541898-A2 | LIVER-SPECIFIC INDUCIBLE PROMOTERS AND METHODS OF USE THEREOF | AskBio Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2002018420-A2 | COFACTORS OF THE PREGNANE X RECEPTOR AND METHODS OF USE | LION BIOSCIENCE AG (DE) | 2002-03-07 | — | — | WO | disclosed |
| US-6294380-B1 | Liver cell clones for use in extracorporeal liver-assist device | JMS CO., LTD. (JP) | 2001-09-25 | — | — | US | disclosed |
| WO-2001051045-A2 | MODULATORS OF THE CONSTITUTIVE ADROSTANE RECEPTOR (CAR): SCREENING AND TREATMENT OF HYPERCHOLESTEROLEMIA | TULARIK INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| EP-1063289-A1 | Liver cell clones for artifical liver and extracorporeal liver assist device | JMS Co., Ltd. (JP) | 2000-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599665-B2 | Gene fusions for control of genetically modified cells | BID, ESR1, BCLAF1 | SMN1; SMN2 535/4885LMNA 566/4885CYP2C9 3900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.